Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Source: SeekingAlpha
2026-03-02 16:57:59 ET
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL March 2, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
-0.36% G/L:
$236.195 Last:
205,760 Volume:
$233.87 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
